In order to thrive, you need to have all of the tools at your fingertips, and that includes evidence-based therapies that go beyond conventional oncology.
To learn more about evidence-based therapies for Pancreatic Cancer, click the orange button to the right.
If you are reading this post then you are probably a pancreatic cancer (PC) patient or caregiver. You probably already know that conventional oncology has little to offer the PC patient and that five-year survival rates for PC are dismal.
When I was diagnosed with my cancer, multiple myeloma, I was also told that it was incurable. That was in early 1994. I agree that PC is challenging but I don’t believe any cancer is incurable.
Try to look at conventional oncology’s inability to treat PC in a positive light. I didn’t do well when I relied exclusively on my oncologist. I began to do much better once I took control of my health.
Please don’t misunderstand me. I think conventional oncology- diagnostic testing, chemotherapy, radiation and even PC surgery called the Whipple Procedure– is all important for you to learn and understand. In fact, the goal of almost all pancreatic patients will be to shrink the tumor in order for it to be surgically removed. Pancreatic cancer is curable usually only after surgical removal of the tumor.
All I am saying is that once I learned to balance conventional and evidence-based non-conventional therapies I did much better. I supplement with Life Extension Super BioCurcumin as this brand and formula have been evaluated and approved by Consumerlab.com and independent testing company.
Please take a moment to watch the short video below in order to learn more about some of these therapies and how they can help you manage your Pancreatic Cancer:
Have you been diagnosed with PC? What stage? What therapies are you considering? Scroll down the page, post a question or comment and I will reply to you ASAP.
“Development of resistance to chemotherapeutic drugs is a major challenge in the care of patients with pancreatic ductal adenocarcinoma (PDAC). Acquired resistance to chemotherapeutic agents in PDAC has been linked to a subset of cancer cells termed ‘cancer stem cells’ (CSCs)…
Accumulating evidence indicates that curcumin, a phenolic compound extracted from turmeric, can overcome de novo chemoresistance and re-sensitize tumors to various chemotherapeutic agents...
Overall, this study indicates clinical relevance for combining curcumin with chemotherapy to overcome chemoresistance in PDAC…”
“A number of preclinical studies have demonstrated anticancer effects of curcumin in various types of tumors, including pancreatic cancer. Curcumin has anticancer effects both alone and in combination with other anticancer drugs (e.g., gemcitabine, 5-fluorouracil, and oxaliplatin), and it has been shown to modulate a variety of molecular targets in preclinical models, with more than 30 molecular targets identified to date..
However, the poor bioavailability of curcumin has been the major challenge to its clinical application. This problem has now been solved by the development of highly bioavailable forms of curcumin (THERACURMIN®), which can induce higher plasma curcumin levels without increased toxicity…”
“The present study demonstrates that water-soluble PEGylated curcumin conjugate that we generated increases the effects of curcumin on inhibition of cellular growth in pancreatic cancer cells. More importantly, the new compound sensitized pancreatic cancer cells to gemcitabine-induced cell apoptosis and growth inhibitory effects…”
“Pancreatic cancer is almost always lethal, and the only U.S. Food and Drug Administration-approved therapies for it, gemcitabine and erlotinib, produce objective responses in <10% of patients. We evaluated the clinical biological effects of curcumin (diferuloylmethane), a plant-derived dietary ingredient with potent nuclear factor-kappaB (NF-kappaB) and tumor inhibitory properties, against advanced pancreatic cancer…
Oral curcumin is well tolerated and, despite its limited absorption, has biological activity in some patients with pancreatic cancer…”